Last updated: 2026-09-06 15:51:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Artiva Biotherapeutics, Inc. (ARTV) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $11,15, with a market capitalization of $552,95M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,22 to $14,53. This page covers its latest market performance, valuation, price trends and company information.
$552,95M | |
$11,02 | |
$17,31 | |
$1,47 | |
$11,13 | |
147,88K | |
-- | |
-- | |
$14,53 | |
$2,22 | |
-- | |
-- |
Artiva Biotherapeutics, Inc. (ARTV) last closed at $11,13 as of 2026-09-04 23:46:00, unchanged from the previous close of $11,13.
During the latest regular trading session, ARTV traded between $1,47 and $17,31, with a volume of 147,88K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Artiva Biotherapeutics, Inc. (ARTV) moved from $11,01 to $11,15, representing a gain of 1,28% ($0,14).
The stock traded between $11,01 and $11,37 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 257,31 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 72,6%
ARTV is currently trading at $11,15, placing it 72,6% of the way from its 52-week low of $2,22 to its 52-week high of $14,53. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 115 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Artiva Biotherapeutics, Inc. (ARTV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.